(Q37785480)

23 August 2017

title

Therapeutic targeting of the prostate cancer microenvironment (English)

1 reference

23 August 2017

1 reference

2

Vassiliki Tzelepi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20818327

7 July 2024

author name string

Maria Karlou

series ordinal

1

1 reference

23 August 2017

Eleni Efstathiou

series ordinal

3

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

full work available at URL

23 August 2017

http://www.nature.com/articles/nrurol.2010.134.pdf

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.134

http://www.nature.com/articles/nrurol.2010.134

7 July 2024

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.134

7 July 2024

published in

Nature Reviews Urology

1 reference

23 August 2017

volume

7

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

494-509

1 reference

Structural characterization of myofibroblasts in the bladder

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Dasatinib inhibits both osteoclast activation and prostate cancer PC-3-cell-induced osteoclast formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Stromal regulation of neoplastic development: age-dependent normalization of neoplastic mammary cells by mammary stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Friends or foes - bipolar effects of the tumour stroma in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

The tumor microenvironment in the post-PAGET era.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Smooth muscle-epithelial interactions in normal and neoplastic prostatic development.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

A new therapy paradigm for prostate cancer founded on clinical observations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Interactions between adult human prostatic epithelium and rat urogenital sinus mesenchyme in a tissue recombination model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Regulation of migration of primary prostate epithelial cells by secreted factors from prostate stromal cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Stromal myofibroblasts are drivers of invasive cancer growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

The stroma reaction myofibroblast: a key player in the control of tumor cell behavior

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Tumor-promoting phenotype of CD90hi prostate cancer-associated fibroblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Evidence that androgen-independent stromal growth factor signals promote androgen-insensitive prostate cancer cell growth in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

The role of tumor microenvironment in prostate cancer bone metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Osteoblasts in prostate cancer metastasis to bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Osteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Androgen-induced Wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

EFFECT OF ORCHIECTOMY AND IRRADIATION ON CANCER OF THE PROSTATE

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Autoradiographic studies of androgen-binding sites in the rat urogenital sinus and postnatal prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Regulation of rat prostate stromal cell myodifferentiation by androgen and TGF-beta1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Effect of increasing ratio of estrogen: androgen on proliferation of normal human prostate stromal and epithelial cells, and the malignant cell line LNCaP.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Stromal-epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Androgen-independent prostate cancer DU145 cells suppress androgen-dependent growth of prostate stromal cells through production of inhibitory factors for androgen responsiveness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Androgen responsiveness of stromal cells of the human prostate: regulation of cell proliferation and keratinocyte growth factor by androgen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Androgen-stimulated human prostate epithelial growth mediated by stromal-derived fibroblast growth factor-10

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Targeting the stromal androgen receptor in primary prostate tumors at earlier stages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Soluble factors derived from stroma activated androgen receptor phosphorylation in human prostate LNCaP cells: roles of ERK/MAP kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Human prostate stromal cells stimulate increased PSA production in DHEA-treated prostate cancer epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Androgen effects on bone metabolism: recent progress and controversies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Sonic hedgehog activates mesenchymal Gli1 expression during prostate ductal bud formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Hedgehog signalling in prostate regeneration, neoplasia and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

The Sonic Hedgehog pathway stimulates prostate tumor growth by paracrine signaling and recapitulates embryonic gene expression in tumor myofibroblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

CXCR4 antagonist inhibits stromal cell-derived factor 1-induced migration and invasion of human pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Hedgehog signaling promotes prostate xenograft tumor growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Sonic hedgehog gene-enhanced tissue engineering for bone regeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Initial modulation of the tumor microenvironment accounts for thalidomide activity in prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

A paracrine requirement for hedgehog signalling in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Naturally occurring small-molecule inhibitors of hedgehog/GLI-mediated transcription

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

The role of fibroblast growth factors and their receptors in prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Fibroblast growth factor-2 mediates transforming growth factor-beta action in prostate cancer reactive stroma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Identification of the fibroblast growth factor receptor of Swiss 3T3 cells and mouse skeletal muscle myoblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Pharmacological inhibition of FGF receptor signaling inhibits LNCaP prostate tumor growth, promatrilysin, and PSA expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Tumor necrosis factor-alpha supports the survival of osteoclasts through the activation of Akt and ERK.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Reduction of c-Src activity by substituted 5,7-diphenyl-pyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Decreased c-Src expression enhances osteoblast differentiation and bone formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Src as a therapeutic target in men with prostate cancer and bone metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Expression of transforming growth factor-beta 1 and growth in soft agar differentiate prostate carcinoma-associated fibroblasts from normal prostate fibroblasts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Insensitivity to transforming growth factor-beta results from promoter methylation of cognate receptors in human prostate cancer cells (LNCaP).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Transforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

The role of transforming growth factor-beta-mediated tumor-stroma interactions in prostate cancer progression: an integrative approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

TGFbeta signaling in growth control, cancer, and heritable disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Expression and distribution of transforming growth factor-beta isoforms and their signaling receptors in growing human bone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Osteoblast-derived TGF-β1 modulates matrix degrading protease expression and activity in prostate cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

In vitro human osteoblast and extracellular matrix changes after transforming growth factor beta 1 treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Osteoblast conditioned media contain TGF-beta1 and modulate the migration of prostate tumor cells and their interactions with extracellular matrix components

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Tranilast inhibits hormone refractory prostate cancer cell proliferation and suppresses transforming growth factor beta1-associated osteoblastic changes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Inhibition of transforming growth factor-beta signaling in human cancer: targeting a tumor suppressor network as a therapeutic strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

A phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody (CAT-152) to prevent scarring after first-time trabeculectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

New experimental markers for early detection of high-risk prostate cancer: role of cell-cell adhesion and cell migration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Integrins in prostate cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Unique expression pattern of the alpha6beta4 integrin and laminin-5 in human prostate carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Specific alterations in the expression of alpha 3 beta 1 and alpha 6 beta 4 integrins in highly invasive and metastatic variants of human prostate carcinoma cells selected by in vitro invasion through reconstituted basement membrane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Integrin-regulated FAK-Src signaling in normal and cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

MEK kinase activity is not necessary for Raf-1 function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Cell-matrix adhesion in vascular development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Imaging of integrins as biomarkers for tumor angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Requirement of vascular integrin alpha v beta 3 for angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Inhibition of alpha(v)beta3 integrin reduces angiogenesis, bone turnover, and tumor cell proliferation in experimental prostate cancer bone metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Insulin-Like Growth Factor (IGF) family and prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Notch signaling: a potential therapeutic target in prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

A role for notch signaling in stromal survival and differentiation during prostate development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

The Notch pathway in prostate development and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Radiation-induced HIF-1alpha cell survival pathway is inhibited by soy isoflavones in prostate cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

c-Src-p38 mitogen-activated protein kinase signaling is required for Akt activation in response to ionizing radiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Drug penetration in solid tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

The hypoxic tumour microenvironment and metastatic progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Hypoxia--a key regulatory factor in tumour growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Dynamics of hypoxia, proliferation and apoptosis after irradiation in a murine tumor model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Hypoxic radiosensitization: adored and ignored

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Androgen Withdrawal in Patients Reduces Prostate Cancer Hypoxia: Implications for Disease Progression and Radiation Response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Expression of BNIP3 correlates with hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha and the androgen receptor in prostate cancer and is regulated directly by hypoxia but not androgens in cell lines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

The relevance of a hypoxic tumour microenvironment in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Tumor hypoxia, DNA repair and prostate cancer progression: new targets and new therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Angiogenesis in life, disease and medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Angiogenesis and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

How the extracellular matrix and macrophages contribute to angiogenesis-dependent diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Microvessel density in prostate carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Angiogenesis as a therapeutic target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.134

Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells

31 March 2020

1 reference

12 December 2020

Indian hedgehog coordinates endochondral bone growth and morphogenesis via parathyroid hormone related-protein-dependent and -independent pathways

1 reference

12 December 2020

Inhibition of transforming growth factor-beta activity decreases angiogenesis in a human prostate cancer-reactive stroma xenograft model

1 reference

12 December 2020

Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium

1 reference

12 December 2020

Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.

1 reference

12 December 2020

Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro

1 reference

12 December 2020

Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms

1 reference

12 December 2020

Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma

1 reference

12 December 2020

Fibroblast growth factor receptor 2 limits and receptor 1 accelerates tumorigenicity of prostate epithelial cells

1 reference

12 December 2020

Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells

1 reference

12 December 2020

Osteoblasts modulate secretion of urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in human prostate cancer cells promoting migration and matrigel invasion.

1 reference

12 December 2020

The characterization of the receptor for endothelial cell growth factor by covalent ligand attachment

1 reference

12 December 2020

SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro

1 reference

12 December 2020

Stromal cell heterogeneity in fibroblast growth factor-mediated stromal-epithelial cell cross-talk in premalignant prostate tumors

1 reference

12 December 2020

Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase, and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry

1 reference

12 December 2020

Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.

1 reference

12 December 2020

Prolonged survival of rats with intracranial C6 gliomas by treatment with TGF-beta antisense gene

1 reference

12 December 2020

SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice

1 reference

12 December 2020

Mitogenic conversion of transforming growth factor-beta1 effect by oncogenic Ha-Ras-induced activation of the mitogen-activated protein kinase signaling pathway in human prostate cancer.

1 reference

12 December 2020

The distribution of secondary growths in cancer of the breast. 1889

1 reference

12 December 2020

Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling.

1 reference

12 December 2020

Activation of the hedgehog pathway in advanced prostate cancer

1 reference

12 December 2020

Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts

1 reference

12 December 2020

Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer

1 reference

12 December 2020

Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer

1 reference

12 December 2020

Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients

1 reference

12 December 2020

Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix.

1 reference

12 December 2020

Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer

1 reference

12 December 2020

Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts

1 reference

12 December 2020

Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: involvement of the insulin like growth factor-1 receptor

1 reference

12 December 2020

Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma.

1 reference

12 December 2020

Comparative gene expression profile analysis of GLI and c-MYC in an epithelial model of malignant transformation.

1 reference

12 December 2020

10

63

4936

X Wu

2003

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.134

7 July 2024

14

59

5002

AF Olumi

1999

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.134

7 July 2024

30

51

3753

M Gleave

1991

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.134

7 July 2024

40

61

5038

J Gao

2001

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.134

7 July 2024

43

61

423

SM Henshall

2001

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.134

7 July 2024

65

62

5867

ID Louro

2002

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.134

7 July 2024

80

60

4245

F Ropiquet

2000

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.134

7 July 2024

85

57

5369

S Feng

1997

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.134

7 July 2024

104

63

375

JM Golas

2003

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.134

7 July 2024

106

59

4834

B Tang

1999

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.134

7 July 2024

114

60

3031

BJ Park

2000

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.134

7 July 2024

115

55

2596

DM Morton

1995

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.134

7 July 2024

139

62

6021

JA Tuxhorn

2002

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.134

7 July 2024

167

63

3755

A Abdollahi

2003

1 reference

https://api.crossref.org/works/10.1038/NRUROL.2010.134

7 July 2024

Identifiers

1 reference

23 August 2017

1 reference